Celularity Inc·4

Jun 23, 10:12 AM ET

Barach Daniele Wolf 4

Research Summary

AI-generated summary

Updated

Celularity (CELU) 10% Owner Daniele Barach Disposes Derivative Rights

What Happened Daniele Barach (reported as Barach Daniele Wolf), a trustee of the Philip & Daniele Barach Family Trust and a >10% owner, recorded the disposition (expiration) of derivative rights representing a total of 2,043,979 Celularity (CELU) Class A shares. The filing shows 1,204,819 shares represented by convertible-note conversion rights and 839,160 shares represented by warrants expired on June 19, 2026; no cash or other consideration was paid in connection with these expirations.

Key Details

  • Transaction date: June 19, 2026; Form 4 filed June 23, 2026 (see timeliness note below).
  • Instruments expired: 1,204,819 shares (conversion rights tied to up to $2,000,000 of convertible notes) and 839,160 shares (warrants contingent on purchasing those notes). Total = 2,043,979 represented shares.
  • Price/value: N/A — no exercise, purchase, or sale proceeds were reported.
  • Ownership after transaction: filing does not state total Class A shares beneficially owned after these expirations; the Trust remained the direct owner of securities reported.
  • Footnotes: F1 describes the convertible-note option expiration (no consideration); F2 explains warrant rights expired because the note option lapsed; F3 notes the securities are/ were held by the Philip & Daniele Barach Family Trust and the reporter is a trustee with voting/dispositive power.
  • Timeliness: Form 4 was filed four calendar days after the June 19 transactions (filed 6/23); this exceeds the typical two-business-day Form 4 filing window and may be considered late.

Context These were expirations of derivative rights (not open-market sales or purchases). For retail investors: expirations like this are administrative — they remove potential future dilution from unexercised instruments but do not reflect a cash sale or an outright purchase by the insider. As a reported >10% owner and trustee of a family trust, this filing reflects trust-held instruments rather than routine executive trading.